*Mao R, Qiu Y, He J-S, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis.* Lancet Gastroenterol Hepatol *2020; **5:** 667--68*---In this Article, due to errors in data extraction, data in figures 2--6 have been updated. The appendix has also been updated. These changes do not materially affect the interpretation. The fifth sentence of the Findings in the Summary should read: "Subgroup analysis showed patients with severe COVID-19 had higher rates of abdominal pain (odds ratio \[OR\] 7·10 \[95% CI 1·93--26·07\]; p=0·003; *I* ^2^=0%) and abnormal liver function including increased ALT (1·89 \[1·30--2·76\]; p=0·0009; *I* ^2^=10%) and increased AST (3·08 \[2·14--4·42\]; p\<0·00001; *I* ^2^=0%) compared with those with non-severe disease.". The last sentence of the Findings should read: "Patients with gastrointestinal involvement tended to have a poorer disease course (eg, acute respiratory distress syndrome OR 2·96 \[95% CI 1·17--7·48\]; p=0·02; *I* ^2^=0%).". In the sixth paragraph of the Results section, data for nausea or vomiting should read: "6% (5--9; range 1--19; *I* ^2^=87%)". The legend for figure 3 should read: "Pooled estimate of the prevalence of abnormal liver chemistry in patients with COVID-19". In the tenth paragraph of the Results section, the second and third sentences should read: "Patients with severe COVID-19 were more likely to present with abdominal pain (OR 7·10 \[95% CI 1·93--26·07\]; p=0·003; *I* ^2^=0%) compared with those with non-severe disease. However, we found no significant difference between patients with severe and non-severe disease in loss of appetite (2·83 \[0·92--8·69\]; p=0·07; *I* ^2^=64%), diarrhoea (1·22 \[0·81--1·84\]; p=0·35; *I* ^2^=0%), or nausea or vomiting (1·11 \[0·63--1·94\]; p=0·71; *I* ^2^=24%).". The first sentence of the 11th paragraph of the Results should read: "We found a higher risk of abnormal liver chemistry including increased ALT (OR 1·89 \[95% CI 1·30-2·76\], p=0·0009; *I* ^2^=10%) and AST (3·08 \[2·14--4·42\]; p\<0·00001; *I* ^2^=0%; figure 6) in patients with severe COVID-19 than in those with non-severe disease.". The last sentence of paragraph 13 in the Results should read: "This trend was further confirmed by the finding that a larger proportion of patients in Hubei had increased total bilirubin concentrations compared with those of patients outside of Hubei (appendix p 11).". In the penultimate paragraph of the Results, the third and fourth sentences should read: "Similarly, children with COVID-19 had a similar risk of liver injury to that of adult patients (9% \[95% CI 3--21\] *vs* 21% \[9--43\]; p=0·0516). However, children were less likely to present with increased ALT and AST compared with adult patients (appendix p 11).". The eighth sentence of paragraph five of the Discussion should read: "We found a higher prevalence of abdominal pain in patients with severe COVID-19 than in those with non-severe disease.". These changes have been made to the online version as of June 15, and the print version is correct.
